- Home
- ARIS vs PHVS Comparison
ARIS vs PHVS Comparison
Compare ARIS & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARIS
- PHVS
- Stock Information
- Founded
- ARIS 2015
- PHVS 2015
- Country
- ARIS United States
- PHVS Netherlands
- Employees
- ARIS N/A
- PHVS N/A
- Industry
- ARIS Water Supply
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- ARIS Utilities
- PHVS Health Care
- Exchange
- ARIS Nasdaq
- PHVS Nasdaq
- Market Cap
- ARIS 828.1M
- PHVS 862.3M
- IPO Year
- ARIS 2021
- PHVS 2021
- Fundamental
- Price
- ARIS $29.01
- PHVS $16.91
- Analyst Decision
- ARIS Buy
- PHVS Strong Buy
- Analyst Count
- ARIS 6
- PHVS 5
- Target Price
- ARIS $27.17
- PHVS $41.60
- AVG Volume (30 Days)
- ARIS 855.7K
- PHVS 50.2K
- Earning Date
- ARIS 05-06-2025
- PHVS 05-07-2025
- Dividend Yield
- ARIS 1.93%
- PHVS N/A
- EPS Growth
- ARIS 36.59
- PHVS N/A
- EPS
- ARIS 0.81
- PHVS N/A
- Revenue
- ARIS $435,444,000.00
- PHVS N/A
- Revenue This Year
- ARIS $8.98
- PHVS N/A
- Revenue Next Year
- ARIS $7.68
- PHVS N/A
- P/E Ratio
- ARIS $36.03
- PHVS N/A
- Revenue Growth
- ARIS 11.05
- PHVS N/A
- 52 Week Low
- ARIS $12.44
- PHVS $14.14
- 52 Week High
- ARIS $32.56
- PHVS $26.57
- Technical
- Relative Strength Index (RSI)
- ARIS 52.98
- PHVS 55.23
- Support Level
- ARIS $25.59
- PHVS $14.49
- Resistance Level
- ARIS $30.95
- PHVS $17.00
- Average True Range (ATR)
- ARIS 2.08
- PHVS 1.32
- MACD
- ARIS 0.06
- PHVS 0.18
- Stochastic Oscillator
- ARIS 52.67
- PHVS 71.95
About ARIS Aris Water Solutions Inc.
Aris Water Solutions Inc is an environmental infrastructure and solutions company that helps customers reduce their water and carbon footprints. It has two primary revenue streams. The Produced Water Handling business gathers, transports, and, unless recycled, handles produced water generated from oil and natural gas production. The Water Solutions business develops and operates recycling facilities to treat, store and recycle produced water.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.